ELTP heads into the final day of April with its commercial debut fading from view and the stock quietly giving back ground — down nearly 6% on the week and 6.6% over the past month to $0.346.
The big catalyst in this window was the early April launch of generic methadone hydrochloride tablets, the company's first commercial product following years of development-stage positioning. The announcement triggered an 8-K filing on April 2 and a flurry of press coverage, yet the stock has declined rather than rallied since. The pattern echoes the company's recent earnings history: the last two earnings-adjacent prints both produced day-one drops of between 7.5% and 10.9%, and the five-day drift was negative in three of the four most recent events. Investors appear willing to acknowledge news but not to pay up for it.
Short interest is not where the story lives here. At just 0.29% of the free float — roughly 2.4 million shares — bear positioning is minimal by any measure, and it has been drifting modestly lower all month, down about 1% week-on-week. Borrowing costs are a modest 4.3%, up slightly from the week prior but well below the 5.4–5.6% range that prevailed through February and early March. Availability is extraordinarily loose — the lending pool holds shares well in excess of what bears would need — so there is no borrow-market tension influencing the price move. The short score of 33.5 is unremarkable; the 52-week high for utilisation was a brief spike to 26.6% on April 9, an anomaly that unwound the same week.
The ownership picture raises a different flag. The largest holder on record, Nasrat Hakim, holds roughly 221 million shares — about 20.6% of the company — with no reported change as of last summer. Below that, Douglas Plassche (EVP) added 2.5 million shares in January 2026, but the most recent insider-trade data shows him selling steadily through 2024 and October 2025, offloading over 2.1 million shares across four transactions at prices ranging from $0.49 to $0.624. The most recent of those sales was October 2025, now more than six months old, so the picture is stale — but the direction of travel for the second-largest named holder has been consistently out, not in.
The factor scorecard adds modest texture. The days-to-cover rank scores in the 90th percentile, reflecting how illiquid a squeeze scenario would be relative to average trading volume — FINRA's last fortnightly reading put days to cover at 3.62 — but that is a structural feature of a micro-cap OTC stock, not an active short-selling signal. The next scheduled earnings event falls at end of June, leaving the methadone launch ramp as the main commercial variable to watch between now and then.
How quickly methadone revenue begins to register in the quarterly numbers — and whether it arrives ahead of the June print — is what the next few weeks of trading are really about.
See the live data behind this article on ORTEX.
Open ELTP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
